Home Depot, Apollo, Oscar, Nutrien, Enovix Trending With Analysts

Analysts are intrested in these 5 stocks: ( (HD) ), ( (ARI) ), ( (OSCR) ), ( (NTR) ) and ( (ENVX) ). Here is a breakdown of their recent ratings and the rationale behind them.

Home Depot is back in the spotlight as analysts restart coverage with a Buy rating and a price objective of $374 per share, well above its recent $312.42 level. The call hinges on Home Depot’s deep ties to professional contractors, who already make up about half of sales and are still showing positive growth, giving the retailer an edge as the housing market normalizes.

Recent deals for SRS Distribution and Gypsum Management Supply have sparked debate, but analysts argue investors shouldn’t “miss the forest for the trees.” While the acquisitions temporarily weigh on returns, they expand Home Depot’s reach into a roughly $700 billion Pro market, and with the stock trading at about 19 times earnings and at a relative trough versus Lowe’s, the pullback is seen as an attractive entry point.

Apollo Commercial Real Estate Finance has emerged from a major reshuffle, and analysts have resumed coverage with a Neutral stance and an $11.50 price objective, just above its $10.99 share price. The company sold a $9 billion loan portfolio to its affiliate Athene at virtually book value, validating its balance sheet and leaving Apollo with a sizable cash pile and a cleaner slate.

Today’s Apollo is essentially a cash-rich shell with about $1.3 billion in cash and a handful of real estate assets, and investors are watching to see which new strategy management chooses. If no plan is in place by the end of 2026, a full breakup is on the table, and with fees temporarily cut and returns historically near 11.5% before COVID, the stock now trades as a waiting game on the next chapter.

Oscar Health draws a more cautious tone, with analysts initiating the stock at a Hold-equivalent rating and a year-end 2026 price range of $19 to $21, reflecting both promise and risk. The company is a pure play on the fast-evolving individual and exchange health insurance market, targeting more than 20% revenue growth by expanding into new regions and capitalizing on major rivals exiting exchanges.

The key question is whether Oscar can hit its 5% margin target by 2027 while navigating shifting government funding and a tougher risk pool. Analysts see near-term operating margins closer to 1–2% and earnings power of about $0.59 to $1.14 over the next two years, but note that if the company eventually reaches its 5% goal, earnings could more than double, making execution the crucial swing factor for investors.

Nutrien is winning back fans on the Street, with one major upgrade to Buy and a new price target of $90, up from $74, as fertilizer markets heat up. Analysts point to tightening crop fundamentals, especially in U.S. corn, where lower acreage and more normal yields could squeeze stocks and support higher prices for farmers and for Nutrien’s products.

Fertilizer prices, particularly nitrogen and phosphate, have surged in recent weeks amid supply disruptions tied to conflict in the Middle East and export restrictions from key producers. While rising input costs and stretched farmer budgets pose headwinds, analysts expect higher nutrient prices to more than offset the pressure over time, supporting stronger cash flow and justifying a higher valuation multiple.

Enovix, once a high-flyer in next-generation batteries, faces a colder reception as analysts downgrade the stock to Sell and withdraw their prior price target. The company is progressing toward qualification with its lead smartphone customer, Honor, which removes one overhang, but the path to meaningful volume has been pushed out, with large-scale commercialization now seen more likely in late 2026 or 2027.

The bigger worry is that Enovix’s vaunted energy density lead is narrowing as entrenched Asian battery makers pour money into similar technologies while enjoying better scale, costs, and customer relationships. With smartphone timelines long, every delay risks missing key product cycles, and analysts fear the current valuation assumes a smooth ramp that may never arrive, especially if other markets like wearables and defense stay too small to move the needle.